These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36202488)

  • 1. Making a Case for the Anti-inflammatory Effects of ACE Inhibitors and Angiotensin II Receptor Blockers: Evidence From Randomized Controlled Trials.
    Issa N
    Mayo Clin Proc; 2022 Oct; 97(10):1766-1768. PubMed ID: 36202488
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
    Dézsi CA
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
    BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
    Ueda S
    J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?
    Ferrario CM; Saha A; VonCannon JL; Meredith WJ; Ahmad S
    Curr Hypertens Rep; 2022 Dec; 24(12):709-721. PubMed ID: 36272015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
    Khoshghamat N; Jafari N; Toloue-Pouya V; Azami S; Mirnourbakhsh SH; Khazaei M; Ferns GA; Rajabian M; Avan A
    Life Sci; 2021 Apr; 270():119118. PubMed ID: 33548284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
    Ritter JM
    BMJ; 2011 Apr; 342():d1673. PubMed ID: 21474511
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should ACE inhibitors and ARBs be used in combination in children?
    Stotter BR; Ferguson MA
    Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypertension in patients with cardiac hypertrophy].
    Kohno M
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():471-7. PubMed ID: 15171418
    [No Abstract]   [Full Text] [Related]  

  • 18. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
    Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
    J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.